[go: up one dir, main page]

MX2017004742A - Métodos para la predicción de niveles de farmacos anti-tnf alfa y formación de autoanticuerpos. - Google Patents

Métodos para la predicción de niveles de farmacos anti-tnf alfa y formación de autoanticuerpos.

Info

Publication number
MX2017004742A
MX2017004742A MX2017004742A MX2017004742A MX2017004742A MX 2017004742 A MX2017004742 A MX 2017004742A MX 2017004742 A MX2017004742 A MX 2017004742A MX 2017004742 A MX2017004742 A MX 2017004742A MX 2017004742 A MX2017004742 A MX 2017004742A
Authority
MX
Mexico
Prior art keywords
tnfa drug
methods
prediction
predicting
drug levels
Prior art date
Application number
MX2017004742A
Other languages
English (en)
Inventor
Singh Sharat
Kondragunta Venkateswarlu
Original Assignee
Nestec Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nestec Sa filed Critical Nestec Sa
Publication of MX2017004742A publication Critical patent/MX2017004742A/es

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/564—Immunoassay; Biospecific binding assay; Materials therefor for pre-existing immune complex or autoimmune disease, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5091—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing the pathological state of an organism
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
    • G01N33/6869—Interleukin
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/94—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving narcotics or drugs or pharmaceuticals, neurotransmitters or associated receptors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/52—Assays involving cytokines
    • G01N2333/54—Interleukins [IL]
    • G01N2333/5421—IL-8
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/52—Assays involving cytokines
    • G01N2333/54—Interleukins [IL]
    • G01N2333/5434—IL-12
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/06—Gastro-intestinal diseases
    • G01N2800/065—Bowel diseases, e.g. Crohn, ulcerative colitis, IBS
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Pathology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • General Physics & Mathematics (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Rehabilitation Therapy (AREA)
  • Rheumatology (AREA)
  • Physiology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

En algunos aspectos, la presente invención proporciona el método para predecir si un sujeto desarrollará autoanticuerpos a un medicamento anti-TNFa durante el transcurso de la terapia con medicamentos anti-TNFa. En otros aspectos, la presente invención proporciona métodos para predecir el nivel de un medicamento anti-TNFa en un sujeto durante el transcurso de la terapia con medicamentos anti-TNFa. En el presente documento también se proporcionan sistemas para predecir los niveles del medicamento anti-TNFa y la probabilidad de la formación de autoanticuerpos durante el transcurso de la terapia con medicamentos anti-TNFa. La presente invención además proporciona métodos para predecir un resultado clínico (por ejemplo, la respuesta endoscópica) de un sujeto con terapia con medicamentos anti-TNFa.
MX2017004742A 2014-10-20 2015-10-19 Métodos para la predicción de niveles de farmacos anti-tnf alfa y formación de autoanticuerpos. MX2017004742A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462065997P 2014-10-20 2014-10-20
US201462086103P 2014-12-01 2014-12-01
PCT/IB2015/058048 WO2016063204A1 (en) 2014-10-20 2015-10-19 Methods for prediction of anti-tnf alpha drug levels and autoantibody formation

Publications (1)

Publication Number Publication Date
MX2017004742A true MX2017004742A (es) 2017-07-20

Family

ID=54540131

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2017004742A MX2017004742A (es) 2014-10-20 2015-10-19 Métodos para la predicción de niveles de farmacos anti-tnf alfa y formación de autoanticuerpos.

Country Status (5)

Country Link
US (3) US10571467B2 (es)
EP (1) EP3210016A1 (es)
CA (1) CA2964857A1 (es)
MX (1) MX2017004742A (es)
WO (1) WO2016063204A1 (es)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201202319D0 (en) 2012-02-10 2012-03-28 Orbsen Therapeutics Ltd Stromal stem cells
MX2017004742A (es) 2014-10-20 2017-07-20 Nestec Sa Métodos para la predicción de niveles de farmacos anti-tnf alfa y formación de autoanticuerpos.
US10124038B2 (en) 2015-03-20 2018-11-13 Orbsen Therapeutics Limited Modulators of syndecan-2 and uses thereof
WO2017122095A1 (en) 2016-01-15 2017-07-20 Orbsen Therapeutics Limited Sdc-2 exosome compositions and methods of isolation and use
EP3652305A2 (en) 2017-07-14 2020-05-20 Orbsen Therapeutics Limited Cd39 stromal stem cells methods of isolation and use
JP7496324B2 (ja) 2018-03-16 2024-06-06 サイファー メディシン コーポレイション 抗ｔｎｆ療法に対する応答性を予測するための方法及びシステム
US10821155B2 (en) 2018-06-27 2020-11-03 Juvena Therapeutics, Inc. Heparin-associated polypeptides and uses thereof
CN114375339A (zh) 2019-05-14 2022-04-19 普罗米修斯生物科学公司 Tl1a患者选择方法、系统和装置
CN114402084A (zh) 2019-06-27 2022-04-26 赛福医药公司 开发用于对患者分层的分类器
CN115379850A (zh) 2019-12-24 2022-11-22 裘美娜治疗公司 再生性多肽及其用途
MX2024000233A (es) 2021-06-21 2024-03-14 Juvena Therapeutics Inc Polipeptidos regenerativos y usos de los mismos.

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5830675A (en) 1993-03-10 1998-11-03 Cedars-Sinai Medical Center Methods for selectively detecting perinuclear anti-neutrophil cytoplasmic antibody of ulcerative colitis, primary sclerosing cholangitis, or type 1 autoimmune hepatitis
ATE193601T1 (de) 1993-03-10 2000-06-15 Cedars Sinai Medical Center Verfahren zum selektiven nachweis von perinuklearen anti-neutrophilen cytoplasmischen antikörpern bei ulzerativen kolitis oder primärer sclerotischer cholangitis
US6218129B1 (en) 1998-05-15 2001-04-17 Prometheus Laboratories, Inc. Inflammatory bowel disease first step assay system
US7919094B2 (en) 2004-06-10 2011-04-05 Omeros Corporation Methods for treating conditions associated with MASP-2 dependent complement activation
US20080026485A1 (en) * 2006-04-18 2008-01-31 Wolfgang Hueber Antibody profiling for determination of patient responsiveness
RU2442171C2 (ru) 2006-09-21 2012-02-10 Промитьюс Лабораториз Инк. Чипы на основе антител для определения множественных трансдукторов сигналов в редких циркулирующих клетках
ES2526211T3 (es) 2007-07-13 2015-01-08 Nestec S.A. Selección de fármacos para la terapia del cáncer de pulmón utilizando matrices basadas en anticuerpos
NZ587420A (en) 2008-02-25 2012-07-27 Prometheus Lab Inc Drug selection for breast cancer therapy using antibody-based arrays
CA2734519C (en) * 2008-08-29 2018-11-13 Centocor Ortho Biotech Inc. Markers and methods for assessing and treating ulcerative colitis and related disorders using a 20 gene panel
JP5718319B2 (ja) 2009-05-14 2015-05-13 ネステク ソシエテ アノニム Ｈｅｒ２標的化療法に対する乳癌細胞の感受性を決定するためのバイオマーカー
WO2010144358A1 (en) 2009-06-08 2010-12-16 Singulex, Inc. Highly sensitive biomarker panels
AU2010273319B2 (en) 2009-07-15 2015-01-22 Nestec S.A. Drug selection for gastric cancer therapy using antibody-based arrays
JP5819307B2 (ja) 2009-10-20 2015-11-24 ネステク ソシエテ アノニム 発癌性融合タンパク質を検出するための近接媒介性アッセイ
CA3108458A1 (en) * 2009-10-26 2011-05-12 Societe Des Produits Nestle S.A. Assays for the detection of anti-tnf drugs and autoantibodies
CN103384828A (zh) 2010-12-23 2013-11-06 雀巢产品技术援助有限公司 使用基于抗体的阵列进行恶性癌症疗法的药物选择
KR20140008397A (ko) * 2011-02-17 2014-01-21 네스텍 소시에테아노님 항-ＴＮＦα 약물에 대한 자가항체 검출을 위한 검정법
EP2908132B8 (en) 2011-03-02 2019-06-12 Nestec S.A. Prediction of drug sensitivity of lung tumors based on molecular and genetic signatures
MX362132B (es) 2011-05-10 2019-01-07 Nestec Sa Metodos para perfilado de actividad de enfermedad para manejo de terapia personalizado.
ES2553456T3 (es) 2011-09-02 2015-12-09 Nestec S.A. Perfilado de proteínas de ruta de señal para determinar una eficacia terapéutica
US20140051184A1 (en) 2012-08-15 2014-02-20 Nestec S.A. Mobility shift assays for detecting anti-tnf alpha drugs and autoantibodies thereto
NZ631007A (en) * 2014-03-07 2015-10-30 Alexion Pharma Inc Anti-c5 antibodies having improved pharmacokinetics
MX2017004742A (es) 2014-10-20 2017-07-20 Nestec Sa Métodos para la predicción de niveles de farmacos anti-tnf alfa y formación de autoanticuerpos.

Also Published As

Publication number Publication date
US10571467B2 (en) 2020-02-25
US20200158725A1 (en) 2020-05-21
US11435347B2 (en) 2022-09-06
US20170315117A1 (en) 2017-11-02
CA2964857A1 (en) 2016-04-28
EP3210016A1 (en) 2017-08-30
WO2016063204A1 (en) 2016-04-28
US20230078652A1 (en) 2023-03-16

Similar Documents

Publication Publication Date Title
MX2017004742A (es) Métodos para la predicción de niveles de farmacos anti-tnf alfa y formación de autoanticuerpos.
WO2015200434A8 (en) Predictive neurodiagnostic methods
PH12017501080A1 (en) User maintenance system and method
MX375557B (es) Método para predecir el resultado de un tratamiento con aflibercept de un paciente que se sospecha que padece un cáncer.
HK1244881A1 (zh) 建立维多珠单坑给药方案以治疗患有易激惹肠病的患者的方法
MX2015001552A (es) Sistemas, dispositivos, y metodos para determinar un nivel de inventario optimo para un articulo con ventas desproporcionalmente dispersadas.
MX2020006388A (es) Biomarcadores para el diagnostico y pronostico de trastornos ectaticos de la cornea.
EP3640643A3 (en) Method for predicting the outcome of a treatment with aflibercept of a patient suspected to suffer from a cancer by measuring the level of a plasma biomarker
UA96595U (uk) Спосіб прогнозування зрощення перелому
HK1237373A1 (en) Predictive neurodiagnostic methods
UA107177U (uk) Спосіб прогнозування перебігу раку передміхурової залози
UA96623U (uk) Спосіб прогнозування зрощення перелому
UA95654U (uk) Спосіб прогнозування зрощення перелому
UA96295U (uk) Спосіб прогнозування зрощення перелому
UA96652U (uk) Спосіб прогнозування зрощення перелому
UA95566U (uk) Спосіб прогнозування зрощення перелому
UA96956U (uk) Спосіб прогнозування зрощення перелому
UA96954U (uk) Спосіб прогнозування зрощення перелому
UA96557U (uk) Спосіб прогнозування зрощення перелому
UA96977U (uk) Спосіб прогнозування зрощення перелому
UA96906U (uk) Спосіб прогнозування зрощення перелому
UA96591U (uk) Спосіб прогнозування зрощення перелому
UA95591U (uk) Спосіб прогнозування зрощення перелому
UA94323U (uk) Спосіб прогнозування незрощення перелому
UA95603U (uk) Спосіб прогнозування зрощення перелому